Bloodlines Series: CAR T-cell Therapy Shows Promise for Smoldering Myeloma
In the CAR-PRISM clinical trial, the CAR T-cell therapy ciltacabtagene autoleucel showed promise for treating high-risk smoldering myeloma.
Progress Against Cancer
In the CAR-PRISM clinical trial, the CAR T-cell therapy ciltacabtagene autoleucel showed promise for treating high-risk smoldering myeloma.
The latest edition of our "From the Bench" series examines creative research approaches presented at the AACR Annual Meeting...
An AACR grant to study menin's structure gave researchers the 3D map they needed to produce new treatments for...
In April 2026, AACR's journals editors highlighted studies on cancer survivors taking GLP-1 agonists, an immunotherapy-boosting bacteria, and more.
Injecting immunotherapy directly into precancerous oral lesions may be an effective way to prevent progression to cancer without surgery.
People with alveolar soft part sarcoma can receive immunotherapy treatment for an extended period without long-term side effects.
In March, AACR's journals editors highlighted studies on the development of pediatric leukemia, the use of low-dose tamoxifen, and...
In February, the editors of AACR's journals highlighted studies on the FDA’s accelerated approval pathway, how metabolism impacts prostate...